Search the Internet          Tips  Sites: Finance, Investment

UK nod news is shot in arm for RPG Life

BS Markets Bureau

The stock of RPG Life Sciences remained locked at the 8 per cent upper circuit at Rs 38.40 following sustained buying in the stock on expectations of better performance and exports in the current year, dealers said.

Analysts said the stock was firm on news that the company's pharma plant received approval from the Medicine Control Authority of the UK. The approval is expected to boost the company's exports, dealers added.

RPG Life Sciences' new pharmaceutical formulations plant at Ankleshwar, Gujarat, has received approval from the MCA enabling it to sell certain pharmaceutical formulations in the European market.

RPG Life Science is a joint venture between G D Searle & Co, US, and Rallis. The company was promoted to introduce a range of G D Searle's products in India.

The company later started manufacturing its own formulations at its bulk drug plant in Thane, Maharashtra.

It has a major presence in pesticides and pharmaceutical industries and has also expanded into the food-additive sector. It enjoys a significant presence in five of the ten largest therapeutic product groups in the country -- anti-dairrhoeals, anti-psychotics, diuretics, antibiotics and anti-spasmodics.

Some of its brands (such as Lomotil and Lomofen) enjoy brand leadership status and others (such as Nufex, Rinostat, Naprosyn and Siloxogene) have a growing presence in their respective segments.

Besides manufacturing a wide range of insecticides, herbicides and fungicides, it has become a brand leader in the synthetic pyrethroids market as well, with its Fenval brand.

In the food additive segment, it manufactures and markets in India, Equal, a low-calorie sweetener from G D Searle & Co, US, eager to build a brand presence in the country.

The company has diversified into manufacture of bulk drugs based on high technology and capital intensive fermentation process and it has successfully assimilated the technology and achieved expected yields in a very short time.

The Sertec division catering to cardio vascular, diabetes and renal therapy has introduced new products including Losatex, Topdip, Acedip, Zert-OD and these products were well accepted by customers.

Powered by

ALSO READ:
The Rediff Budget Special
The Rediff-Business Standard Special
Money

Tell us what you think of this report